Overexpression of Claudin proteins in esophageal adenocarcinoma and its precursor lesions

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 1, 2006, Pages 24-30

  Montgomery, Elizabeth ^a,d   Mamelak, Adam J ^a   Gibson, Michael ^a   Maitra, Anirban ^a   Sheikh, Salwa ^b   Amr, Samir S ^b   Yang, Stephen ^a   Brock, Malcolm ^a   Forastiere, Arlene ^a   Zhang, Shengle ^a   Murphy, Kathleen M ^a   Berg, Karin D ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DHAHRAN HEALTH CENTER   (Saudi Arabia)

^c LABORATORY CORPORATION OF AMERICA   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Dysplasia; Gene expression; Intestinal metaplasia

Indexed keywords

CLAUDIN; CLAUDIN 3; CLAUDIN 4;

ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MICROARRAY; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; TISSUE MICROARRAY; UPREGULATION; VALIDATION STUDY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33644761728     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000151933.04800.1c     Document Type: Article

References (28)

1. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287-1289.
2. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA. 1993;270:1320.
3. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin North Am. 2002;11:235-256.
4. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
5. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
6. Michl P, Buchholz M, Rolke M, et al. Claudin- 4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology. 2001;121:678-684.
7. Long H, Crean CD, Lee WH, et al. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001;61:7878-7881.
8. Michl P, Barth C, Buchholz M, et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003;63:6265-6271.
9. Kominsky SL, Argani P, Korz D, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene. 2003;22:2021-2033.
10. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003;9:2567-2575.
11. Morita K, Furuse M, Fujimoto K, et al. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA. 1999;96:511-516.
12. Katahira J, Inoue N, Horiguchi Y, et al. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol. 1997;136:1239-1247.
13. Kokai-Kun JF, McClane BA. Determination of functional regions of Clostridium perfringens enterotoxin through deletion analysis. Clin Infect Dis. 1997;25(Suppl 2):S165-S167.
14. Kokai-Kun JF, McClane BA. Deletion analysis of the Clostridium perfringens enterotoxin. Infect Immun. 1997;65:1014-1022.
15. Kokai-Kun JF, Benton K, Wieckowski EU, et al. Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis. Infect Immun. 1999;67:5634-5641.
16. McClane BA, Wnek AP, Whitaker-Dowling P. Interferon pretreatment enhances the sensitivity of Vero cells to Clostridium perfringens type A enterotoxin. Microb Pathog. 1987;3:195-206.
17. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
18. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000;60:6281-6287.
19. Al Moustafa AE, Alaoui-Jamali MA, Batist G, et al. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene. 2002;21:2634-2640.
20. Rendon-Huerta E, Valenzano MC, Mullin JM, et al. Comparison of three integral tight junction barrier proteins in Barrett's epithelium versus normal esophageal epithelium. Am J Gastroenterol. 2003;98:1901-1903.
21. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol. 2004;121:226-230.
22. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-1895.
23. Sampliner RE. Barrett's esophagus, a complication of GERD. Curr Treat Options Gastroenterol. 2002;5:45-50.
24. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
25. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA. 2002;287:1982-1986.
26. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287:1972-1981.
27. Sonoda N, Furuse M, Sasaki H, et al. Clostridium perfringens enterotoxin fragment removes specific Claudins from tight junction strands: evidence for direct involvement of Claudins in tight junction barrier. J Cell Biol. 1999;147:195-204.
28. Wieckowski EU, Wnek AP, McClane BA. Evidence that an approximately 50-kDa mammalian plasma membrane protein with receptor-like properties mediates the amphiphilicity of specifically bound Clostridium perfringens enterotoxin. J Biol Chem. 1994;269:10838-10848.